| Hazard Information | Back Directory | [Uses]
Immuno modulator-1 (compound 22) inhibits TNFα and IL-2 secretion in human peripheral blood mononuclear cells (hPBMC), with IC50 values of 4.7 and 26 nM, respectively. Immuno modulator-1 shows hERG potassium channel blocking effect, with Inhibitory percentage of 20% at 3 μM[1]. | [in vivo]
Immuno modulator-1 (compound 22) (1 mg/kg (IV), 5 mg/kg (PO); once) has an oral bioavailability of 30% in Male Sprague-Dawley rats[1]. | Animal Model: | Male Sprague-Dawley rats[1] | | Dosage: | 1 mg/kg (IV), 5 mg/kg (PO) | | Administration: | IV (2 mL/kg), PO (10 mL/kg); once (Pharmacokinetic Analysis) | | Result: | Pharmacokinetic Parameters of Immuno modulator-1 in male Sprague-Dawley rats[1].
| IV (1 mg/kg) | PO (5 mg/kg) | | Cmax (ng/mL) | | 1437 | | AUC0-24 (ng/mL?h) | | 13029 | | CL (mL/min/kg) | 2.2 | | | Vss (L/kg) | 0.36 | | | F (%) | | 30% |
|
| [IC 50]
IL-2 | [References]
[1] Chen Xiangyang, et al. Heterocyclic immunomodulator. Patent, WO2022007659A1. |
|
|